20.500.12556/RUL-144741 The effect of vitamin D levels on the course of COVID-19 in hospitalized patients – a 1-year prospective cohort study [version 1; peer review: awaiting peer review] Background: The aim of the current study was to assess the patients with COVID-19 and the impact of vitamin D supplementation on the course of COVID-19. Methods: This prospective cohort study included patients hospitalized due to COVID-19 between December 2020 and December 2021. Patients' demographic, clinical, and laboratory parameters were analysed. Results: 301 participants were enrolled in the study. 46 (15,3%) had moderate, and 162 (53,8%) had severe COVID-19. 14 (4,7%) patients died, and 30 (10,0%) were admitted to the ICU due to disease worsening. The majority needed oxygen therapy (n=224; 74,4%). Average vitamin 25(OH)D3 levels were below optimal at the admittance, and vitamin D deficiency was detected in 205 individuals. More male patients were suffering from vitamin D deficiency. Patients with the more severe disease showed lower levels of vitamin 25(OH)D3 in their blood. The most severe group of patients had more symptoms that lasted significantly longer with progressing disease severity. This group of patients also suffered from more deaths, ICU admissions, and treatments with dexamethasone, remdesivir, and oxygen. Conclusion: Patients with the severe course of COVID-19 were shown to have increased inflammatory parameters, increased mortality, and higher incidence of vitamin D deficiency. The results suggest that the vitamin D deficiency might represent a significant risk factor for a severe course of COVID-19. vitamin D COVID-19 severity supplementation dexamethasone remdesivir resnost dopolnjevanje deksametazon emdesivir COVID-19 vitamin D true false true Angleški jezik Slovenski jezik Članek v reviji 2023-03-10 07:37:46 2023-03-10 07:37:50 2023-03-11 03:36:46 0000-00-00 00:00:00 2023 0 0 15 str. Vol. 12 art. 254 2023 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 577.161.2 2046-1402 10.12688/f1000research.131730.1 144681219 740ef75c-ee32-4555-b5d7-130c92cb4079_131730_-_david_stubljar.pdf 740ef75c-ee32-4555-b5d7-130c92cb4079_131730_-_david_stubljar.pdf 1 F6D22E55B951DC143981A82C5D2CCB7B 8af690e23c5dee6d52cb26fc7cae676843cf67920f83c0da3b70de0c7dddb168 62f48afc-bf0e-11ed-a314-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=167225 https://f1000research.com/articles/12-254/v1 1 0a356275-bf0e-11ed-a314-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=167224 Fakulteta za farmacijo Medicinska fakulteta 0 0 0